British Journal of Clinical Pharmacology · 1980 · 16 citations · 12 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPharmacodynamicsPsychopharmacologyDrug DispositionHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive PharmacologyAntihypertensive TreatmentBlood PressureBlood Pressure PharmacodynamicsPharmacologic Treatment Of WithdrawalPharmacological Management Of WithdrawalPretreatment
1. Guanfacine 3-6 mg daily lowered blood pressure in five essential hypertensives and also reduced saliva production. 2. Plasma and urinary noradrenaline values were significantly reduced throughout the 8-10 weeks of treatment. 3. On substitution of placebo tablets for guanfacine, blood pressure increased over a 2-4 d period to reach but did not significantly exceed pretreatment levels. 4. After withdrawal of guanfacine plasma noradrenaline standing was significantly higher than the pretreatment level (P < 0.05) after 4 days. Saliva production was significantly higher than the pretreatment level on day 3 and day 4 of withdrawal. 5. Guanfacine is an effective antihypertensive drug with a spectrum of actions similar to clonidine. However, in abrupt withdrawal blood pressure returned to the pretreatment level over a 2-4 d period.
12
Noradrenaline Release from Isolated Nerve Granules
U. S. von Euler, F. Lishajko · Acta Physiologica Scandinavica · 1961 · 997 citations
A sensitive radioenzymatic assay for norepinephrine in tissues and plasma
David P. Henry, Barbra J. Starman, David G. Johnson et al. · Life Sciences · 1975 · 475 citations
Clinical pharmacology and pharmacokinetics of clonidine
C. T. Dollery, D. S. Davies, G. H. Draffan et al. · Clinical Pharmacology & Therapeutics · 1976 · 275 citations